The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies
Subscribe To Our Newsletter & Stay Updated
